Vitamin D: modulator of the immune system

1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), the active form of vitamin D, is known to regulate calcium and phosphorus metabolism, thus being a key-player in bone-formation. However 1,25(OH)₂D₃ also has a physiological role beyond its well-known role in skeletal homeostasis. Here, we describe 1,25(OH)₂D₃ as an immunomodulator targeting various immune cells, including monocytes, macrophages, dendritic cells (DCs), as well as T-lymphocytes and B-lymphocytes, hence modulating both innate and adaptive immune responses. Besides being targets, immune cells express vitamin D-activating enzymes, allowing local conversion of inactive vitamin D into 1,25(OH)₂D₃ within the immune system. Taken together, these data indicate that 1,25(OH)₂D₃ plays a role in maintenance of immune homeostasis. Several epidemiological studies have linked inadequate vitamin D levels to a higher susceptibility of immune-mediated disorders, including chronic infections and autoimmune diseases. This review will discuss the complex immune-regulatory effects of 1,25(OH)₂D₃ on immune cells as well as its role in infectious and autoimmune diseases, more in particular in tuberculosis and type 1 diabetes (T1D).

Introduction

The Nobel Prize in Chemistry in 1928 was given to Adolf Windaus on account of his work on the constitution of sterols and their connection with vitamins. The vitamin in question was vitamin D, which already had a longstanding history before Windaus studied it. The clinical disorder resulting from vitamin D deficiency during infancy and childhood has been known since the mid-17th century. In that period, the cause of rickets was unknown, but it was endemic in England in the southwest cities of Dorset and Somerset, areas that were heavily polluted by industrial smoke and smog. It was only by the beginning of the 20th century, with the description of the anti-rachitic properties of cod-liver oil and UV irradiation (2 sources of vitamin D), and the use of biochemical tests in the study of rickets, that lack of vitamin D was finally identified as the leading cause of this disease. Thereafter, vitamin D was ultimately recognized as a central regulator of calcium homeostasis and bone metabolism and nowadays it is well understood that vitamin D deficiency in adults results in poorly mineralized skeletal matrix, a symptom known as osteomalacia.

During the past decades, our knowledge of the vitamin D metabolism has greatly evolved and the discovery of vitamin D receptors (VDRs) as well as of vitamin D-activating enzymes in cell types other than those involved in mineral and bone homeostasis strongly indicates a more diverse role for vitamin D than originally accepted. Indeed, activation of these VDRs has so-called non-classical effects, which include the modulation of growth, differentiation status, and function of a variety of cells, exposing additional roles for vitamin D in the regulation of immune responses, cardiovascular processes, and in cancer prevention [1•, 2]. With the growing appreciation of these non-classical effects of vitamin D and their importance for human health, the high prevalence of vitamin D insufficiency or hypovitaminosis D in many populations across the globe is a worrying awareness [3•, 4•]. Vitamin D deficiency is known to cause osteoporosis and muscle weakness, increasing the risk for fractures due to falls, especially in elderly [5]. Moreover, hypovitaminosis D is associated with an increased risk of multiple malignancies, metabolic and cardiovascular diseases, and immune disorders such as autoimmune diseases and high infection rates [6, 7, 8, 9, 10].

In the present review, we summarize the current knowledge on the role of vitamin D as regulator of the immune system, including its effects on a cellular level. Furthermore, we give an overview of the immunological mechanisms linking vitamin D to protection against infectious and autoimmune diseases such as tuberculosis and T1D respectively. In addition, the prospective application of vitamin D as a therapeutic agent is discussed.

In humans, vitamin D can be obtained from two distinct sources, either from diet or by UV-mediated synthesis in the epidermal layer of the skin. Therefore, by definition, vitamin D cannot be considered as a true vitamin but rather as a pro-hormone. Two forms of vitamin D can be obtained by nutritional intake: vitamin D₂ (also known as ergocalciferol) is present in fungi/yeast, while vitamin D₃ (also known as cholecalciferol) is found in foods from animal origin. Only few foods naturally contain significant amounts of vitamin D. For example cod-liver oil and oily fish are considered as rich sources, whereas butter, cream, and egg yolk contain only small amounts. Human and cow's milk, on the contrary, are poor sources of vitamin D [11]. Despite the fact that vitamin D₃ can be obtained by nutrition, the most important source of this pro-hormone is the skin, which has a great capacity to produce vitamin D₃ upon sunlight exposure. In the skin, UV rays promote photolytic cleavage of 7-dihydrocholesterol (7-DHC) into pre-vitamin D₃, which is subsequently converted by a spontaneous thermal isomerization into vitamin D₃ [12]. After synthesis, vitamin D and its metabolites are bound to a carrier molecule, known as the vitamin D binding protein (DBP), for systemic transport [13].

Regardless of the source of vitamin D, it needs to be hydroxylated twice in order to become biologically active [14] (Figure 1). Vitamin D is first hydroxylated in the liver at the carbon 25-position by 25-hydroxylase. Several cytochrome P450 (CYP) isoforms have been proposed to accomplish this hydroxylation step (including the mitochondrial CYP27A1 and the microsomal CYP2R1, CYP3A4, and CYP2J3), but CYP2R1 is suspected to be the high-affinity 25-hydroxylase [15]. Little is known about the regulation of these 25-hydroxylases, but since 25(OH)D₃ generally reflects vitamin D nutritional status, this enzyme is believed to be poorly regulated. As 25(OH)D₃ is the major circulating form of vitamin D, having a half-life of approximately 2 weeks, this metabolite is considered as the primary indicator of vitamin D status. In healthy humans, 25(OH)D₃ is present in serum at concentrations in the range of 30–50 ng/mL. Individuals with 25(OH)D₃ serum levels <30 ng/mL are believed to suffer from vitamin D insufficiency, while levels <15 ng/mL are proposed to define vitamin D deficiency. Severe vitamin D deficiency, with 25(OH)D₃ concentrations <5 ng/mL, is frequently accompanied by the presence of osteomalacia and rickets [16]. Importantly, as a fat-soluble vitamin, 25(OH)D₃ can also be stored in muscles and adipose tissue. The second hydroxylation, mainly occurring in the kidney and catalyzed by 1-α-hydroxylase (CYP27B1), generates the bioactive metabolite 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) or calcitriol (reviewed in [14]). CYP27B1-activity is positively regulated by calcium, phosphate, and their regulating hormones (calcium, parathyroid hormone (PTH), calcitonin, growth hormone (GH), and insulin-like growth factor (IGF)), while negative regulators of this enzyme include phosphate, fibroblast growth factor (FGF)-23, klotho, and 1,25(OH)₂D₃ itself (reviewed in [14]). For instance, low serum calcium levels elicit PTH-release by the parathyroid glands, which stimulates renal CYP27B1-activity and thus 1,25(OH)₂D₃-production. Mechanisms by which 1,25(OH)₂D₃ corrects serum calcium levels include a reduction of renal calcium excretion, increased intestinal calcium absorption, and stimulation of osteoclast maturation to release calcium from the bones. When normal calcium levels are obtained, PTH release – and therewith the CYP27B1 activity – is switched off. Importantly, 1,25(OH)₂D₃ limits its own activity by inducing 24-hydroxylase (CYP24) [17], which executes the first step of vitamin D catabolism and thus prevents excessive vitamin D signaling.

1,25(OH)₂D₃ exerts its actions by binding to the VDR, a member of the nuclear receptor superfamily (reviewed in [14]). Similarly to other members of this receptor family, VDR possesses two discrete domains, the N-terminal DNA-binding domains (DBD) and the C-terminal ligand-binding domain (LDB). High-affinity binding of 1,25(OH)₂D₃ to the LBD induces heterodimerization of VDR with the retinoid X receptor (RXR). Subsequently, this VDR-RXR heterodimer binds to specific DNA sequence elements, so-called vitamin D responsive elements (VDREs) identified as direct repeats of PuG(G/T)TCA motifs separated by 3 bp (DR3), in the promoter-region of vitamin D responsive genes. Depending on the target gene, either co-activators or co-repressors are attracted to the complex to induce or repress RNA polymerase II-mediated gene transcription.

Of interest, VDRs are not only present in different tissues (Figure 2), such as bone, skin, intestine, and kidneys but also non-classical organs like brain, eyes, heart, pancreatic islets (β-cells), immune cells, muscle, adipose tissue, thyroid, parathyroid, and adrenal glands (reviewed in [1]). Importantly, many of these non-classical tissues also express vitamin D-activating enzymes, hence, allowing these non-classical actions to occur via local activation of vitamin D.

In fact, several of these vitamin D target organs are implicated in the development of diabetes (e.g. β-cells, immune cells, skeletal muscle, and adipose tissue) and its secondary complications (e.g. kidney, eyes, and heart), pointing towards therapeutic strategies for vitamin D in the prevention/intervention of type 1 diabetes (T1D) and, possibly type 2 diabetes (T2D), as well as their related health concerns.